Glaukos Corporation's stock surged 24.02% during intraday trading on Thursday, extending a significant rally that began in the post-market and pre-market sessions.

The dramatic move follows the ophthalmic therapy firm's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. The company reported an adjusted loss per share of $0.18, beating the consensus estimate for a $0.27 loss. Furthermore, net sales for the quarter jumped 41% year-over-year to $150.6 million, well above estimates.

In a key positive development, management raised its full-year 2026 net sales guidance to a range of $620 million to $635 million, up from the previous forecast. The strong performance was driven by products iDose TR and Epioxa, with the glaucoma segment showing particularly robust growth. The positive earnings report prompted multiple analyst firms, including JPMorgan, Stifel, Truist, Mizuho, Wells Fargo, BTIG, and Needham, to raise their price targets on the stock.